StockNews.AI
IFRX
StockNews.AI
187 days

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

1. InflaRx initiated a public offering of ordinary shares and pre-funded warrants. 2. Net proceeds target clinical development of vilobelimab and INF904. 3. The offering's success depends on market conditions. 4. Guggenheim Securities acts as book-running manager for the offering. 5. Effective shelf registration by SEC facilitates this capital raise.

7m saved
Insight
Article

FAQ

Why Neutral?

Market offerings can stabilize or dilute stock prices. Previous offerings by similar firms led to mixed outcomes.

How important is it?

This offering could affect funding and project timelines, critical for IFRX's future.

Why Short Term?

Immediate effects from the capital raise may influence stock volatility. Historical examples show swift reactions to public offerings.

Related Companies

IVRXBMYABBV
February 13, 2025 16:01 ET  | Source: InflaRx N.V. JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the Company’s ordinary shares. The purchase price of each pre-funded warrant will equal the price per share at which ordinary shares are being sold to the public in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. All ordinary shares and pre-funded warrants in the offering are to be sold by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. The Company expects to grant the underwriters a 30-day option to purchase additional ordinary shares at the public offering price, less the underwriting discount. The Company intends to use the net proceeds from the offering primarily to fund clinical development of its pipeline candidates, including vilobelimab and INF904, and for general corporate purposes.  Guggenheim Securities, LLC is serving as book-running manager for the proposed offering. A shelf registration statement relating to the ordinary shares and pre-funded warrants being sold in this offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on July 11, 2023. The offering will be made only by means of a prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available at the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals, Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx). Contacts: InflaRx N.V.Jan Medina, CFAVice President, Head of Investor RelationsEmail: IR@inflarx.de  MC Services AGKatja Arnold, Laurie Doyle, Dr. Regina LutzEmail: inflarx@mc-services.euEurope: +49 89-210 2280US: +1-339-832-0752 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Related News